Bristol-myers Squibb Compnay

Bristol-myers Company

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK (no. 4) Limited

Purdue Research Foundation

Viiv Healthcare UK Limited

Sing-Yuen Sit

Jie Chen

Ny Sin

Nicholas A Meanwell

Yan Chen

Alicia Regueiro-Ren

Jacob Swidorski

John J Wright

Paul Michael Scola

Li-Qiang Sun

Zheng Liu

Brian Lee Venables

Richard A Hartz

Piyasena Hewawasam

William John Pitts

Carolyn Diane Dzierba

Junqing Guo

Amy C Hart

John E Macor

Guanglin Luo

Alan Xiangdong Wang

Xiangdong Alan Wang

Li Xu

Kai Xie

Scott Hunter Watterson

Graham S Poindexter

Jianliang Shi

Murugaiah Andappan Murugaiah Subbaiah

Andrew Charles Good

Steven H Spergel

Jeffrey Allen Campbell

Kenneth M Boy

Neelakantan Balasubramanian

Michael E Mertzman

Yazhong Huang

Marc A Bruce

Ira B Dicker

Beata Nowicka-Sans

Peter J Brown

Yong-Jin Wu

John E Starrett, Jr

Scott W Martin

Zhizhen Barbara Zheng

Hua Gong

Jason M Guernon

Hongfeng Deng

Carolyn A Weigelt

Li-Quang Sun

R Thomas Swann

Swanee E Jacutin-Porte

Jeff A Field

James Guy Breitenbucher

Mendi A Morton

Alicia Regueiro-ren

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Indazole carboxamides as kinase inhibitors

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1)

Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Aminotriazolopyridines as kinase inhibitors

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications. 

Aminopyrrolotriazines as kinase inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from Ccycloalkyl, Ccycloalkenyl, Cspirocycloalkyl, Cspirocycloalkenyl, Coxacycloalkyl, Cdioxacycloalkyl, Coxacycloalkenyl, Cdioxacycloalkenyl, Ccyclodialkenyl, Coxacyclodialkenyl, Coxaspirocycloalkyl and Coxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is &#x2014;Calkyl-halo. These compounds are useful for the treatment of HIV and AIDS.

Triterpenoids with HIV maturation inhibitory activity

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.

C-3 and C-17 modified triterpenoids as HIV-1 inhibitors

Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX). 

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, azadecaline derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.

Azadecalin derivatives as inhibitors of human immunodeficiency virus replication

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:  These compounds are useful for the treatment of HIV and AIDS.

C17-aryl substituted betulinic acid analogs

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I and II: These compounds are useful for the treatment of HIV and AIDS.

Extended betulinic acid analogs

Hepatitis C virus inhibitors are disclosed having the general formula: 

Hepatitis C virus inhibitors

Growing community of inventors

Meriden, CT, United States of America

Sing-Yuen Sit